Galvani Bioelectronics

Galvani Bioelectronics is a pioneering medical research company based in Stevenage, Hertfordshire, UK, dedicated to developing bioelectronic medicines. We’re transforming lives through precision neuromodulation, combining GlaxoSmithKline’s life science expertise with Verily Life Sciences’ innovative software and electronics. Our focus is on implant-based therapies that directly modulate specific neural signals to organs central in chronic disease, offering safe, precise, and minimally invasive treatment options. We are currently enrolling patients in clinical studies for Rheumatoid Arthritis, Bladder Dysfunction, and other conditions, utilizing connected software to optimize therapy delivery. Galvani Bioelectronics represents a significant advancement in treating chronic diseases through targeted neuromodulation.

We specialize in immunomodulatory and non-immunomodulatory therapies, addressing a range of conditions including Rheumatoid Arthritis, Bladder Dysfunction, COPD, Multiple Sclerosis, Hypertension, SLE, Sleep Apnea, Psoriatic Arthritis, Type II Diabetes, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, and Type 1 Diabetes.

Galvani’s approach leverages cutting-edge technology – small, efficient wireless electronics and keyhole surgery – to deliver these therapies with minimal invasiveness. Our commitment to innovation and patient well-being drives our research and development efforts, aiming to improve the lives of individuals suffering from debilitating chronic illnesses.